S100A9 Interaction with TLR4 Promotes Tumor Growth
Eva Källberg(Lund University), Tomas Leanderson(Lund University), Pernilla Wikström(Umeå University), Thomas Vogl(Goethe University Frankfurt), Anders Bergh(Umeå University), Johannes Roth(University of Münster), Per Björk(Active Biotech (Sweden)), Fredrik Ivars(Lund University), David Liberg(Active Biotech (Sweden)), Anders Olsson(Linköping University)
Cited by 138
Related Papers
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
|New England Journal of Medicine|2012|2k
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
|The Lancet|2014|750
Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock
|Nature Immunology|2003|363
Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides
|PLoS Biology|2009|358
Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia
|New England Journal of Medicine|2010|334